Two-thirds of newly approved prescription drugs reviewed by the Institute for Clinical and Economic Review between 2022 and 2025 were launched at prices exceeding ICER's cost-effectiveness thresholds.

From the articlecontent frameAlso in Most new drugs are still too costly at launch, ICER says